Tigris Pharmaceuticals is a Bonita Springs, Fla.-based drug development company focused on anticancer therapeutics, including lead compound Aminoflavone pro-drug (AFP-464) and GGTI-2418. AFP-464 has shown growth inhibitory activity in tumor cell line screening, with breast, ovarian, lung and renal lines exhibiting particular sensitivity, and has demonstrated in vivo antitumor activity in multiple xenograft mouse models. A multi-center Phase I ascending dose clinical study of AFP-464 was completed in Europe at Institut Gustave-Roussy and Jules Bordet Institute. The company is conducting a multi-center Phase I dose escalation trial for GGTI-2418 at Abramson Cancer Center (University of Pennsylvania) and Indiana University Melvin and Bren Simon Cancer Center. Tigris intends to use proceeds from its recent financing to advance its clinical product pipeline and expects to initiate a multi-site Phase II breast cancer study in 2010. The company completed a private placement of Series C Convertible Preferred Stock raising approximately $6.5M.

Total raised

$7M

Funding rounds

1

Latest round

Series C

Latest activity

Sep 2010